COMMUNIQUÉS West-GlobeNewswire

Clover Health to Participate in Upcoming 2025 Citi Global Healthcare Conference
17/11/2025
WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/11/2025
MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth’s Novel AI-Powered Breast Cancer Detection Workflow
17/11/2025
Largest real-world analysis of AI-driven breast cancer screening in U.S. history 1 demonstrates increased cancer detection rate with consistent benefits across patient populations LOS ANGELES and SOMERVILLE, Mass., Nov [...]
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
17/11/2025
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
17/11/2025
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the [...]
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock
17/11/2025
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring [...]
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
17/11/2025
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare [...]
LifeMD Reports Third Quarter 2025 Results
17/11/2025
Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million. [...]
Tilray Brands Publishes New Investor Presentation Highlighting Leadership Across Beverage, Cannabis and Wellness Industries, Showcasing Its Global Growth Strategy and Transformation into a Diversified CPG Powerhouse Shaping the Future of Consumer Products
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands”, “Tilray” or “the Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the [...]
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
17/11/2025
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of [...]
Invivyd Announces Proposed Public Offering of Common Stock
17/11/2025
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd [...]
Kraig Biocraft Laboratories Fulfilling Order for Customized Spider Silk Application from Leading Performance Sports Brand
17/11/2025
Company to deliver spider silk yarns for elite-tier athletic application ANN ARBOR, Mich., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in [...]
Protext Mobility, Inc. (OTC: TXTM) Announces Strategic TruLeaf Partnership & Next-Level Innovation
17/11/2025
FORT LAUDERDALE, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“Protext” or the “Company”) is proud to announce a strategic Letter of Intent (LOI) with TruLeaf, marking a pivotal moment in [...]
Neocis Unveils Next-Generation AI-Powered Robotic System for Dental Implants
17/11/2025
Yomi® S and YomiPlan® AI Platform Now FDA-Cleared, Offering Unprecedented Precision, Efficiency, and Access for Dentists and Patients MIAMI, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Neocis ® , the pioneer behind the first and [...]
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH) , a clinical-stage biotechnology company developing an innovative research platform based [...]
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
17/11/2025
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer NANTES, France, [...]
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedopi® dans le cancer du poumon non à petites cellules
17/11/2025
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedopi® dans le cancer du poumon non à petites cellules NANTES, le [...]
New therapeutic approach to facilitate healing of bed sores
17/11/2025
Researchers from UBC and Vancouver Coastal Health are developing natural plant compounds into a healing gel that could speed up recovery and prevent wounds from returning VANCOUVER, British Columbia, Nov. 17, 2025 ( [...]
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
17/11/2025
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of [...]

Pages